Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Evista
Generic Name Raloxifene
Other Brand Name Evista
Packing 28
Manufacturer Eli Lilly
Form Tablet
Strength 60mg
Country

  • 28 tabs 60mg $47.32
Available online
More Views

Customers also bought

  • Generic Arimidex, Anastrozole

    Generic Name:Anastrazole
    Form:Tablet
< >

1

Similar Product

  • Generic Evista, Raloxifene

    Generic Name:Raloxifene
    Form:Tablet
    Out of Stock
< >

1

Details

Introduction

Evista tablet affects the patient's bone formation cycle and its breakdown in the body while it reduces the damage and loss of bone tissues. This helpful drug is popularly used for osteoporosis treatment especially for postmenopausal women and it is also good to reduce the invasive cell tissues of breast cancer.


Use

This drug medicine is used for medication and typically good for osteoporosis prevention in postmenopausal women. It helps in the reduction of fast growth breast cancer link with women suffering from postmenopausal and osteoporosis.


Side effects

Get urgent medical assistance once the patient is experiencing side effects such as sudden numbness, chess pain, weakness, problem with speech and vision, swelling body parts like legs, fever, sore throat, chills, flu signs, severe pain when urinating or felt it in lower back. Same situation requires the help of a physician if the patient got some hot flashes, leg pain, nausea, runny nose, vomiting, stomach pain, joint pain, aching and spinning feeling with dizziness.


Contraindication

This drug is not good for oral treatment for those who have allergic reactions towards this drug medicine or to any of its components that can aggravate the patient's allergies.


storage

Keeping Evista tablet in a room temperature free from heat, moistures, and safe from the children to reach is a better way to stay the good condition and affectivity of this drug medicine.


Composition

Evista as raloxifene tablet has raloxifene HCl of 60 mg, carnauba wax, titanium dioxide, aluminum lake of FD&C Blue No. 2, anhydrous lactose, modified pharmaceutical glaze, crospovidone, lactose monohydrate, hypromellose, polyethylene glycol, propylene glycol, polysorbate 80, povidone, and magnesium stearate.


Important Precautions

This drug medicine can increase the risk of blood clots formation in the patient's veins. The risk is greater if the existing risk factors such as obesity, smoking, family history, blood type disorders and other forms of history shows that a patient is not advisable to take the treatment of this kind of drug medicine same with those who have a surgery has a major illness. Those patients who experience severe vaginal bleeding must consult a doctor before taking this drug medicine. Women with deep thrombosis on veins or has pulmonary embolism, blood disorders like antiphospholipid syndrome or factor V Leiden, heart failures, breast cancers, hypertrigyceridaemia and other severe diseases must take precautionary measures before taking this drug medicine.


Dosage and administration

Taking this medicine must on the basis of doctor's prescription. Never take large amounts of medicine for longer time without proper prescription of the healthcare provider. Patients who are advisable to take Evista take with or without food. A patient can take Evista any time of the day but oral administration must take it on the same time of each regular day. If the tablets are in the form of packed blister cards, taking the medicine is best done without miss or confusion if the 15 tablets in every blister card are having a label using the different days in a week. A patient must keep on taking one tablet per day not unless changed according to the doctor's advice. The tablet at the middle of the card blister should be the last tablet for the patient to take before taking a new blister card. If a patient needs to undergo a surgery, he must take a minimum of 72 hours to stop taking the Evista tablet and the surgeon must know too that his patient is taking this drug medicine.